On Tuesday, Shares of Itau Unibanco Holding SA (ADR)(NYSE:ITUB), subtract -1.14% and closed at $11.23 in the last trading session. The last trading range of the stock ranges between $11.17 and $11.40. Itaú Unibanco Holding S.A. provides a range of financial products and services to individuals and corporate clients in Brazil and internationally. The company operates in three segments: Retail Banking, Wholesale Banking, and Activities with the Market + Corporation. It accepts time, savings, and demand deposits; and offers personal, payroll, vehicle, and mortgage loans, in addition to credit cards. The company also provides asset administration, custody and bookkeeping, consortium, investment banking, and electronic payment means services, in addition to private banking services. In addition, it offers property, casualty, and life insurance products, in addition to reinsurance products; pension plans; and consumer finance credit, in addition to capitalization, leasing, and brokerage services. Itaú Unibanco Holding S.A. has 4,891 branches and client service branches; 94 digital branches; and 2 6,412 automated teller machines.
Dow Chemical Co (NYSE:DOW), dropped 1.07% and closed at $51.86 in the last trading session. The last trading range of the stock ranges between $51.74 and $52.75. The company’s Market capitalization is $59.10 Billion with the total Outstanding Shares of 1.13 Billion. Monsanto Company (MON) and Dow AgroSciences LLC, a wholly-owned partner of The Dow Chemical Company (DOW), declared recently that the companies have reached a non-exclusive global option and licensing agreement on Dow AgroSciences’ EXZACT™ Precision Technology® Platform for research and commercial development of new crop solutions across Monsanto Company’s research portfolio.
EXZACT technology, which Dow AgroSciences has developed under an exclusive license and partnershipagreement in plants with Sangamo BioSciences, Inc., facilitates the creation of crop varieties and lines having improved traits.
“Monsanto is happy to pursue applications of this genome-editing technology for the development of new plant discoveries and solutions for farmers,” said Tom Adams, Ph.D., biotechnology lead for Monsanto. “Zinc finger nucleases are a well-established technology for gene editing and this license, together with our existing and other licensed technology, will allow us to pursue product development while further enabling our growing body of research in this emerging field.”